Aldeyra Therapeutics, Inc. SEC filings ALDX
Aldeyra Therapeutics, Inc. has 647 filings in SEC EDGAR's recent list, going back to Oct 6, 2005. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 24, 2024 | — |
| CORRESP | Letter to the SEC | Apr 22, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2024 | — |
| EFFECT | Filing | Apr 15, 2021 | — |
| CORRESP | Letter to the SEC | Apr 13, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2021 | — |
| D | Filing | Feb 11, 2019 | — |
| CT ORDER | Filing | Oct 4, 2018 | — |
| EFFECT | Filing | Jul 27, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2018 | — |
| CORRESP | Letter to the SEC | Jul 25, 2018 | — |
| EFFECT | Filing | Jan 19, 2017 | — |
| EFFECT | Filing | Jan 19, 2017 | — |
| EFFECT | Filing | Sep 1, 2015 | — |
| CORRESP | Letter to the SEC | Aug 28, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2015 | — |
| EFFECT | Filing | May 7, 2015 | — |
| EFFECT | Filing | Apr 7, 2015 | — |
| EFFECT | Filing | Apr 7, 2015 | — |
| D | Filing | Feb 5, 2015 | — |
| D | Filing | Jan 29, 2015 | — |
| CT ORDER | Filing | May 2, 2014 | — |
| EFFECT | Filing | May 1, 2014 | — |
| CORRESP | Letter to the SEC | Apr 29, 2014 | — |
| CORRESP | Letter to the SEC | Apr 29, 2014 | — |
| CORRESP | Letter to the SEC | Apr 22, 2014 | — |
| CORRESP | Letter to the SEC | Apr 22, 2014 | — |
| CORRESP | Letter to the SEC | Apr 10, 2014 | — |
| CORRESP | Letter to the SEC | Apr 10, 2014 | — |
| CORRESP | Letter to the SEC | Apr 8, 2014 | — |
| CORRESP | Letter to the SEC | Apr 8, 2014 | — |
| CERTNAS | Auto-generated paper document | Apr 7, 2014 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2014 | — |
| 8-A12B/A | Filing | Mar 24, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2014 | — |
| CORRESP | Letter to the SEC | Mar 17, 2014 | — |
| 8-A12B | Filing | Mar 4, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2014 | — |
| CORRESP | Letter to the SEC | Jan 15, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2014 | — |
| DRS/A | Filing | Dec 19, 2013 | — |
| DRS | Filing | Dec 4, 2013 | — |
| D | Filing | Jan 3, 2013 | — |
| REGDEX | Auto-generated paper document | Aug 1, 2008 | — |
| REGDEX | Auto-generated paper document | Oct 6, 2005 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Concord, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1341235
- Former names
- Aldexa Therapeutics, Inc. (until Mar 4, 2014); Neuron Systems Inc (until Aug 1, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.